Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458911 | 0.91 | AKR1C3 (0.64) | ALDH1A1NPC1RAB9AGAAKDM4E | |
| SCHEMBL8290497 | 0.86 | NPC1 (0.68) | ALDH1A1NPC1RAB9AGAALMNA | |
| SCHEMBL29256038 | 0.85 | NPC1 (0.67) | ALDH1A1NPC1RAB9AGAAKDM4E | |
| SCHEMBL2285784 | 0.85 | ALDH1A1 (0.76) | ALDH1A1NPC1GAAKDM4ELMNA | |
| SCHEMBL4801328 | 0.84 | MEN1 (0.68) | ALDH1A1GAAKDM4ETSHRLMNA | |
| SCHEMBL2636523 | 0.84 | MAPT (0.70) | ALDH1A1GAAKDM4ETSHRLMNA | |
| SCHEMBL6955039 | 0.84 | ALDH1A1 (0.68) | ALDH1A1GAAKDM4ETSHRLMNA | |
| SCHEMBL10568862 | 0.84 | POLB (0.57) | ALDH1A1NPC1RAB9AGAATSHR | |
| SCHEMBL4799931 | 0.84 | PKM (0.78) | ALDH1A1NPC1RAB9AGAATSHR | |
| SCHEMBL29145909 | 0.84 | PKM (0.78) | ALDH1A1NPC1RAB9ALMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102491941-B | Preparation method of N-methoxy-N-methyl-1-p-toluenesulfonyl piperidine-4-amide | UNIV NORTHWEST NORMAL | 2014-01-22 | — | — | CN | claimed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | claimed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | claimed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| CN-115141138-B | Method for constructing fluoride by decarboxylation of alkyl carboxylic acid | 中山大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-115141138-A | Method for constructing fluoride by decarboxylation of alkyl carboxylic acid | 中山大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-112028814-B | Method for preparing amine compound based on novel catalytic Curtius rearrangement reaction | 南京大学 | 2022-03-15 | — | — | CN | disclosed |
| WO-2020252457-A1 | PROCESSES AND COMPOUNDS FOR THE DECARBOXYLATIVE AMINATION OF REDOX-ACTIVE ESTERS WITH DIAZIRINES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| CN-112028814-A | Method for preparing amine compound based on novel catalytic Curtius rearrangement reaction | 南京大学 | 2020-12-04 | — | — | CN | disclosed |
| US-6696418-B1 | ANIMAL GROWTH REGULATORS SUCH AS 6-AMINO-2-(2-((1-BENZENE SULFONYL-PIPERIDINE-4-CARBONYL)-AMINO)-3-(1H-INDOL-3-YL)-PROPIONYLAMINO) -HEXANOIC ACID TERT-BUTYL ESTER, ADMINISTERED TO MODULATE CELL DIFFERENTIATION | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | ALDH1A1 3407/4885NPC1 1706/4885RAB9A 3088/4885 |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | ALDH1A1 3284/4885NPC1 1804/4885RAB9A 3102/4885 |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | ALDH1A1 3284/4885NPC1 1804/4885RAB9A 3102/4885 |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | ALDH1A1 721/4885NPC1 447/4885RAB9A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.